

# Johann K Hitzler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7735370/publications.pdf>

Version: 2024-02-01

86  
papers

2,396  
citations

279798

23  
h-index

214800

47  
g-index

88  
all docs

88  
docs citations

88  
times ranked

3233  
citing authors

#	ARTICLE	IF	CITATIONS
1	GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. <i>Blood</i> , 2003, 101, 4301-4304.	1.4	291
2	Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. <i>Nature Genetics</i> , 2001, 28, 220-221.	21.4	268
3	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015, 47, 1326-1333.	21.4	233
4	Origins of leukaemia in children with Down syndrome. <i>Nature Reviews Cancer</i> , 2005, 5, 11-20.	28.4	192
5	Comparison of Long-Term Neurocognitive Outcomes in Young Children With Acute Lymphoblastic Leukemia Treated With Cranial Radiation or High-Dose or Very High-Dose Intravenous Methotrexate. <i>Journal of Clinical Oncology</i> , 2006, 24, 3858-3864.	1.6	159
6	Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and meta-analysis. <i>Leukemia Research</i> , 2014, 38, 460-468.	0.8	113
7	Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. <i>Lancet Oncology</i> , The, 2014, 15, 841-851.	10.7	108
8	Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. <i>Blood</i> , 2017, 129, 3304-3313.	1.4	71
9	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. <i>Journal of Clinical Oncology</i> , 2021, 39, 1437-1447.	1.6	56
10	Frequency and outcome of pediatric acute lymphoblastic leukemia with <i>ZNF384</i> gene rearrangements including a novel translocation resulting in an <i>ARID1B/ZNF384</i> gene fusion. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1915-1921.	1.5	55
11	Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. <i>British Journal of Haematology</i> , 2006, 133, 646-648.	2.5	54
12	Acute Leukemias in Children with Down Syndrome. <i>Pediatric Clinics of North America</i> , 2008, 55, 53-70.	1.8	49
13	Mapping the cellular origin and early evolution of leukemia in Down syndrome. <i>Science</i> , 2021, 373, .	12.6	42
14	Brain structure, working memory and response inhibition in childhood leukemia survivors. <i>Brain and Behavior</i> , 2017, 7, e00621.	2.2	41
15	Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 893-897.	2.0	39
16	Acute Leukemias in Children with Down Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 19-34.	2.2	35
17	Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with down syndrome. <i>Pediatric Blood and Cancer</i> , 2009, 52, 14-19.	1.5	34
18	Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2017, 96, 1449-1456.	1.8	32

#	ARTICLE	IF	CITATIONS
19	Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia. <i>Science Translational Medicine</i> , 2014, 6, 236ra62.	12.4	30
20	Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 973-982.	1.5	29
21	Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. <i>British Journal of Haematology</i> , 2013, 162, 98-106.	2.5	28
22	Neurocognitive Late Effects of Chemotherapy in Survivors of Acute Lymphoblastic Leukemia: Focus on Methotrexate. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2015, 24, 25-32.	0.6	28
23	Acute megakaryoblastic leukemia in Down syndrome. <i>Pediatric Blood and Cancer</i> , 2007, 49, 1066-1069.	1.5	27
24	Outcome of transplantation for acute lymphoblastic leukemia in children with down syndrome. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1126-1128.	1.5	24
25	Characterizing neurocognitive late effects in childhood leukemia survivors using a combination of neuropsychological and cognitive neuroscience measures. <i>Child Neuropsychology</i> , 2018, 24, 999-1014.	1.3	24
26	Treatment of young children with CNS-positive acute lymphoblastic leukemia without cranial radiotherapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1881-1885.	1.5	17
27	Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. <i>Blood Advances</i> , 2019, 3, 1647-1656.	5.2	17
28	B cell acute lymphoblastic leukemia cells mediate RANK-RANKL-dependent bone destruction. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	17
29	Treatment of acute myeloid leukemia in children: A practical perspective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28979.	1.5	16
30	High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. <i>Blood</i> , 2021, 138, 2337-2346.	1.4	16
31	CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation. <i>Pediatric Blood and Cancer</i> , 2004, 42, 24-29.	1.5	15
32	Transient myeloproliferative disorder in neonates without Down syndrome: case report and review. <i>European Journal of Haematology</i> , 2015, 94, 456-462.	2.2	14
33	Juvenile Chronic Myelogenous Leukemia Multilineage CD34+ Cells: Aberrant Growth and Differentiation Properties. <i>Stem Cells</i> , 1996, 14, 690-701.	3.2	13
34	Neuropsychological late effects of treatment for acute leukemia in children with Down syndrome. <i>Pediatric Blood and Cancer</i> , 2015, 62, 854-858.	1.5	13
35	Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come. <i>Haematologica</i> , 2019, 104, 7-9.	3.5	13
36	Quantitative MRI outcomes in child and adolescent leukemia survivors: Evidence for global alterations in gray and white matter. <i>NeuroImage: Clinical</i> , 2020, 28, 102428.	2.7	13

#	ARTICLE	IF	CITATIONS
37	The Outcome of Allogeneic Hematopoietic Cell Transplantation for Children with FMS-Like Tyrosine Kinase 3 Internal Tandem Duplicationâ€“Positive Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 172-175.	2.0	11
38	Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. <i>Pediatric Blood and Cancer</i> , 2006, 47, 206-209.	1.5	10
39	Brain Development and Heart Function after Systemic Single-Agent Chemotherapy in a Mouse Model of Childhood Leukemia Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 6040-6052.	7.0	10
40	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. <i>Blood</i> , 2021, 138, 2304-2304.	1.4	10
41	Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 466-472.	2.5	9
42	Transient Leukemia in Newborns Without Down Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, e261-e263.	0.6	8
43	Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1949-1953.	1.5	8
44	Cognitive and behavioral risk factors for low quality of life in survivors of childhood acute lymphoblastic leukemia. <i>Pediatric Research</i> , 2021, 90, 419-426.	2.3	8
45	Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131. <i>Blood</i> , 2015, 126, 2502-2502.	1.4	8
46	Assessment of the Outcomes Associated with Periprocedural Anticoagulation Management in Children with Acute Lymphoblastic Leukemia. <i>Journal of Pediatrics</i> , 2014, 164, 1201-1207.	1.8	7
47	Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children's Oncology Group (COG) report.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10510-10510.	1.6	7
48	Infections in children with down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group. <i>Infectious Agents and Cancer</i> , 2013, 8, 47.	2.6	6
49	Pre-Morbid Developmental Vulnerabilities in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). <i>Pediatric Blood and Cancer</i> , 2015, 62, 2183-2188.	1.5	6
50	Need for new thinking: Treatment of relapsed leukemia in children with Down syndrome. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27644.	1.5	6
51	Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children's Oncology Group (COG) Phase III AAML0431 Trial. <i>Blood</i> , 2014, 124, 278-278.	1.4	6
52	High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada. <i>Blood</i> , 2018, 132, 1410-1410.	1.4	5
53	Conventional Reinduction/Consolidation-Type Therapy Versus Short Course High Intensity Combination Chemotherapy As Post-Induction Treatment for Children with Relapsed Acute Lymphoblastic Leukemia. Early Results of Study ALL-REZ BFM 2002. <i>Blood</i> , 2011, 118, 871-871.	1.4	5
54	Value of flow cytometric analysis of peripheral blood samples in children diagnosed with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26738.	1.5	4

#	ARTICLE	IF	CITATIONS
55	GATA1 – A Player in Normal and Leukemic Megakaryopoiesis. <i>Pediatric Research</i> , 2002, 52, 831-831.	2.3	3
56	Lumbar spinal fluid collections in children treated with intrathecal chemotherapy: Elevated CSF protein as a diagnostic clue. <i>Pediatric Blood and Cancer</i> , 2008, 51, 295-298.	1.5	3
57	Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28044.	1.5	3
58	High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction. <i>Blood</i> , 2019, 134, 118-118.	1.4	3
59	Early Mortality In Hyperleukocytosis In Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2013, 122, 2647-2647.	1.4	3
60	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10509-10509.	1.6	3
61	Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system. <i>Cell Reports Medicine</i> , 2021, 2, 100470.	6.5	3
62	How essential are in-person clinic visits during maintenance treatment of children with acute lymphoblastic leukemia?. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29713.	1.5	3
63	When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3-ITD AML. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29278.	1.5	2
64	The Clonal Hematopoietic Spectrum of Down Syndrome and ML-DS. <i>Blood</i> , 2018, 132, 3839-3839.	1.4	2
65	Unusual lymphoid malignancy and treatment response in two children with Down syndrome. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27822.	1.5	1
66	Understanding Pre-Leukemia in Trisomy 21 Human HSC and Modeling Progression Towards Down Syndrome Associated Leukemia Using CRISPR/Cas9 at Single Cell Resolution. <i>Blood</i> , 2019, 134, 2531-2531.	1.4	1
67	Secondary Cytogenetic Abnormalities and Outcome in Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2005, 106, 1450-1450.	1.4	1
68	Important Role of Routine Cerebrospinal Fluid Examination in Diagnosing Central Nervous System Relapse during Maintenance Therapy in Pediatric Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2005, 106, 870-870.	1.4	1
69	Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study. <i>Blood</i> , 2015, 126, 172-172.	1.4	1
70	Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration. <i>Blood</i> , 2016, 128, 1687-1687.	1.4	1
71	Tisagenlecleucel Therapy Is Safe and Effective for Children with Down Syndrome with ALL in First Relapse. <i>Blood</i> , 2021, 138, 4820-4820.	1.4	1
72	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2020, 136, 44-45.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Cancer among Persons with Down Syndrome. International Review of Research in Mental Retardation, 2010, , 128-164.	0.7	0
74	Origin of Leukemia in Children with Down Syndrome. , 2016, , 109-131.		0
75	Detection of a clone-specific <i>GATA1</i> mutation to monitor treatment response and involvement of a monozygotic twin in myeloid leukemia of Down syndrome. Pediatric Blood and Cancer, 2017, 64, e26439.	1.5	0
76	GATA1 mutations Outside the Blast Cell Population in Transient Leukemia of Down Syndrome. Blood, 2011, 118, 2562-2562.	1.4	0
77	Estimated long-term outcomes in children newly diagnosed with standard risk acute lymphoblastic leukemia (ALL) based on similarly treated members of the childhood cancer survivor study (CCSS) cohort.. Journal of Clinical Oncology, 2013, 31, 10032-10032.	1.6	0
78	The Outcome Of Allogeneic Hematopoietic Cell Transplantation In Children With FLT3/ITD-Positive Acute Myelogenous Leukemia. Blood, 2013, 122, 2163-2163.	1.4	0
79	Differences of Somatic Mutations and Gene Expression in Blasts of Transient Leukemia and Acute Myeloid Leukemia of Down Syndrome. Blood, 2014, 124, 2364-2364.	1.4	0
80	Functional and Molecular Consequences of Trisomy 21 on Human Fetal Hematopoiesis. Blood, 2018, 132, 1317-1317.	1.4	0
81	Postnatally Acquired Mutations Underlie the Progression of Transient Leukemia to Myeloid Leukemia of Down Syndrome. Blood, 2018, 132, 442-442.	1.4	0
82	Inactivation of Stage-Specific B-Cell Commitment Genes Generates Distinct Molecular Subtypes of BCR-ABL1 Lymphoblastic Leukemia. Blood, 2018, 132, 569-569.	1.4	0
83	How Important Are in-Person Clinic Visits during Maintenance Therapy for Pediatric Acute Lymphoblastic Leukemia?. Blood, 2021, 138, 2998-2998.	1.4	0
84	Risks of late mortality and morbidity among survivors of childhood acute leukemia with Down syndrome: A population-based cohort study. Cancer, 2021, , .	4.1	0
85	A Human Model of Down Syndrome Associated Leukemia Reveals Different Cell of Origins for Initiation and Progression. Blood, 2020, 136, 11-12.	1.4	0
86	Abstract 2002: A genome-wide association study identifies novel sepsis risk loci in children with Down syndrome-associated acute lymphoblastic leukemia: A report from the Children's Oncology Group. Cancer Research, 2022, 82, 2002-2002.	0.9	0